🔎 Trials Near Me

Akèy › Glomeruloskleroz fokal segmantè › North Carolina › Durham

Etid klinik pou Glomeruloskleroz fokal segmantè nan Durham, NC

8 etid pou Glomeruloskleroz fokal segmantè ap chèche patisipan nan sit nan ak bò kote Durham (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

Ap rekriteFaz 3
  • Duke University Medical Center, Durham
Laj 12 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07220083

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

Ap rekriteFaz 2
  • UNC Kidney Center- Site Number : 8400021, Chapel Hill · 10 mi lwen
Laj 16 a 75 · Tout sèks · Mizajou Sep 23, 2026 · NCT06500702

Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System

Ap rekrite
  • University of North Carolina, Chapel Hill · 10 mi lwen
Jiska laj 75 · Tout sèks · Mizajou Aug 28, 2026 · NCT04065438

Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

Ap rekrite
  • University of North Carolina, Chapel Hill · 10 mi lwen
Jiska laj 21 · Tout sèks · Mizajou Aug 28, 2026 · NCT02235857

Nephrotic Syndrome Study Network

Ap rekriteEtid obsèvasyon
  • University of North Carolina at Chapel Hill, Chapel Hill · 10 mi lwen
Jiska laj 80 · Tout sèks · Mizajou Jun 10, 2026 · NCT01209000

NEPTUNE Match Study

Ap rekrite
  • University of North Carolina Chapel Hill, Chapel Hill · 10 mi lwen
Laj 1 a 80 · Tout sèks · Mizajou Jun 10, 2026 · NCT04571658

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

Ap rekriteFaz 2
  • Duke Molecular Physiology Institute, Durham
  • University of North Carolina at Chapel Hill, Chapel Hill · 10 mi lwen
Laj 1 a 17 · Tout sèks · Mizajou May 12, 2026 · NCT05003986

A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB

Ap rekriteFaz 3
  • University of North Carolina, Chapel Hill · 10 mi lwen
Laj 12 a 80 · Tout sèks · Mizajou Feb 3, 2026 · NCT05183646

Etid Glomeruloskleroz fokal segmantè nan lòt vil

Lòt etid nan Durham

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.